Wells Fargo Maintains Overweight on Relay Therapeutics, Raises Price Target to $15
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Eva Fortea Verdejo maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and raises the price target from $13 to $15.
Wells Fargo analyst Eva Fortea Verdejo maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and raises the price target from $13 to $15.